CABG surgery clinical trials results

artery grafts versus saphenous vein grafts
CARRPO, 2009 NCT00159991	total arterial revascularization using internal thoracic and radial arteries versus conventional revascularization using left internal thoracic artery and vein grafts	patients with multivessel or isolated left main disease referred for elective or urgent CABG	open Follow-up duration: 11.1 months
aspirin versus placebo
McEnany, 1982	aspirin 1200 versus placebo	patients undergoing coronary bypass grafting	double blind Follow-up duration: 22m
Lorenz, 1984	aspirin 100 mg/d versus placebo	patients undergoing CABG	double blind Follow-up duration: 4m
GESIC (aspirin), 1990	aspirin 150 mg daily versus placebo	patients undergoing CABG	double blind Follow-up duration: 28d
Sydney, 1991	aspirin 324 mg daily versus placebo	patients undergoing CABG	double blind Follow-up duration: 12m
Hockings, 1993	aspirin 100 versus placebo	patients undergoing CABG	double blind Follow-up duration: 6m
aspirin + dipyridamol versus control
Pantely, 1979	aspirin 325 mg three times a day + dipyridamole 75 mg three times a day versus control	patients undergoing aortocoronary saphenous-vein bypass-graft surgery	open Follow-up duration: 6m
Brussels, 1987	aspirin 200 + dipiridamol 400 (H) versus		Follow-up duration: 12m
Czech, 1986	aspirin 1000 + dipiridamol 225 versus control (no medication)	Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less	open Follow-up duration: 12m
Des Moines, 1980	aspirin 20 + dipiridamol 100 versus		Follow-up duration: 12m
aspirin + dipyridamol versus placebo
GESIC (aspirin+dipyridamol), 1990	aspirin 50 mg + dipyridamole 75mg 3 times daily versus placebo	patients undergoing CABG	double blind Follow-up duration: 28d Spain
Brooks, 1985	aspirin 990 mg and dipyridamole 225 mg daily versus placebo	patients undergoing coronary bypass grafting	double blind Follow-up duration: 12m
Mayo-A, 1984	aspirin 975 + dipiridamol 225 versus placebo	patients undergoing coronary bypass grafting	double blind Follow-up duration: 12m
Wadsworth, 1985	aspirin 975 mg/d + dipiridamol 225 mg/d, aspirin 975 mg/d versus placebo	coronary bypass patients	double blind Follow-up duration: 12m
Basel, 1989	aspirin 50 + dipiridamol 400 versus placebo	patients who had aortocoronary vein bypass surgery	double blind Follow-up duration: 9m
Leeds-B, 1985	aspirin 990 + dipiridamol 225 (W) versus placebo	patients undergoing aorta-coronary bypass grafting for disabling angina	double blind Follow-up duration: 6m
Thaulow, 1987	aspirin 975 + dipiridamol 225 versus placebo	Patients scheduled to receive at least three aortocoronary venous bypass grafts	double blind Follow-up duration: 3m
clopidogrel+aspirin versus aspirin
CASCADE, 2009 NCT00228423	aspirin 162 mg plus clopidogrel 75 mg daily for 1 year versus aspirin 162 mg plus placebo daily	patients after CABG involving at least two saphenous vein grafts	double blind Follow-up duration: 1 y
dipyridamol versus control
Toronto dipyridamole, 1987	dipiridamol 400 versus control	patients undergoing elective coronary artery bypass grafting	Follow-up duration: 48h
dipyridamol versus placebo
Ekestrom, 1990	dipiridamol 100 mg orally q.i.d. versus placebo	patients undergoing coronary bypass surgery	double blind Follow-up duration: 12m
edifoligide pretreatment versus placebo
PREVENT IV, 2005 NCT00042081	saphenous vein grafts pretreated edifoligide versus placebo	patients undergoing isolated CABG surgery with at least two vein grafts	double blind Follow-up duration: 12 to 18 months US
off-pump versus on-pump
Al-Ruzzeh b, 2006	off-pump versus coronary artery bypass grafting surgery using cardiopulmonary bypass	patients requiring primary isolated coronary artery bypass grafting surgery	open with blinded assessment Follow-up duration: 6 months UK
Alwan, 2004	beating heart revascularization versus arrested heart revascularization	patients undergoing CABG	open Follow-up duration: In-hospital/30-day mortality
Ascione, 2006	off-pump coronary artery bypass grafting versus artery bypass grafting with cardiopulmonary bypass	patient undergoing CABG	open Follow-up duration: In-hospital
Ascionee, 2005	off-pump CABG versus on-pump CABG	patient undergoing CABG	open Follow-up duration: In-hospital
Baker, 2001	off pump surgery using the Octopus II stabilizing system versus conventional CABG cardiopulmonary bypass	elective patients requiring surgery for double or triple vessel disease	open
BBS (Moller), 2010 NCT00120991	off-pump CABG versus on-pump CABG	patients > 54 years of age with three-vessel coronary artery disease with EuroSCORE of 5-16 undergoing elective or sub-acute coronary artery bypass grafting	open blind assessor Follow-up duration: 30 days
BHACAS I (Ascione), 1999	off-pump versus on-pump	cardiac surgery candidates	open with blinded assessment Follow-up duration: 25 months
BHACAS II (Angelini), 2002	off-pump versus on-pump	patients with myocardial infarction in the past month or who required grafting of the circumflex artery distal to the first obtuse marginal branch	open with blinded assessment Follow-up duration: 13.7 months
Caputo, 2002	beating heart surgery (off-pump) versus conventional CABG with cardiopulmonary bypass	patients undergoing coronary artery bypass grafting	open Follow-up duration: In-hospital
Carrier, 2003	off-pump CABG versus on-pump CABG	high-risk patients	open Follow-up duration: In-hospital/30-day mortality
Covino, 2001	versus		open Follow-up duration: In-hospital
Czerny, 2000	versus		open
Czerny b, 2001	versus		open
Diegeler, 2000	coronary artery bypass operation without cardiopulmonary bypass (off-pump CABG) versus conventional coronary artery bypass operation using cardiopulmonary bypass	cardiac surgery candidates	open Follow-up duration: In-hospital
DOORS, 2009 NCT00123981	Off-Pump Coronary Artery Bypass Grafting versus on-pump CABG	elderly patients	open Follow-up duration: 30 days
Dorman, 2004	versus		open
Gasz, 2004	versus		open
Gerola, 2001	off-pump coronary artery bypass versus on-pump CABG	low-risk patients undergoing CABG	open Follow-up duration: In-hospital/30-day mortality
Gu, 1998	minimally invasive coronary artery bypass grafting versus conventional coronary artery bypass grafting with cardiopulmonary bypass	patients with isolated stenosis of the left anterior descending coronary artery	open Follow-up duration: In-hospital
Guler, 2001	versus		open
Gulielmos, 1999	off-pump coronary artery bypass with median sternotomy or off-pump procedure and lateral minithoracotomy versus conventional technique or lateral minithoracotomy and cardiopulmonary bypass	patients with coronary artery single-vessel disease	open Follow-up duration: 3 months
Jares, 2006	off-pump CABG versus on-pump CABG	patients scheduled for coronary bypass grafting	open Follow-up duration: 24 h
Khan, 2004	off-pump CABG versus conventional "on-pump" surgery	patient undergoing CABG	open Follow-up duration: 3 months
Kobayashi, 2005	off-pump CABG versus on-pump CABG	patients referred for elective primary CABG	open Follow-up duration: 30 days
Kunes, 2007	off-pump CABG versus on-pump CABG	patient undergoing CABG	open Follow-up duration: 7 days
Lee, 2003	off-pump CABG versus conventional on-pump CABG	patients undergoing CABG	open
Legare, 2004 NCT00216957	off-pump CABG versus on-pump CABG	patients undergoing CABG	open Follow-up duration: 3.8 years
Lingaas, 2003	off-pump CABG versus on-pump CABG	patient undergoing CABG	open Follow-up duration: 12 months
Matata, 2000	off-pump versus on-pump	cardiac surgery candidates	open Follow-up duration: In-hospital
Michaux, 2006	off-pump CABG versus on-pump CABG	patients scheduled for elective coronary artery bypass surgery	open Follow-up duration: 30 days
Motallebzadeh, 2004	off-pump CABG versus on-pump CABG	patients admitted for CABG	open Follow-up duration: In-hospital
Motallebzadeh b, 2006	off-pump CABG versus on-pump CABG	patients admitted for elective coronary artery bypass graft surgery	open Follow-up duration: 6 months
Muneretto, 2003	versus		open
Niranjan, 2006	off-pump CABG with or without cell saver blood transfusion versus on-pump CABG with or without cell saver blood transfusion	patient undergoing CABG	open Follow-up duration: In-hospital
OCTOPUS (van Dijk), 2002	off-pump surgery versus on-pump surgery	patients with predominantly single- or double-vessel coronary disease	open with blinded assessment Follow-up duration: 5 years the Netherlands
Ozkara, 2007	off-pump CABG versus on-pump CABG	patients admitted for elective CABG	open Follow-up duration: In-hospital
Paparella, 2006	off-pump CABG versus on-pump CABG	patient undergoing CABG	open Follow-up duration: In-hospital
Parolari, 2003	versus		open
Parolari b, 2003	versus		open
Penttila, 2001	off-pump CABG versus on-pump CABG	patients requiring CABG	open Follow-up duration: In-hospital
PRAGUE 4 (Widimsky), 2004	off pump versus on pump	cardiac surgery candidates	open Follow-up duration: 1 y
PROMISS (Uva), 2010	off-pump versus on-pump	patients between 30 and 90 years of age with multi-vessel coronary artery disease undergoing CABG with at least three distal coronary anastomoses	open Follow-up duration: 5 weeks (498 days)
Puskas, 2004	versus		open
Raja b, 2003	on-pump CABG versus off-pump CABG	patients undergoing CABG	open Follow-up duration: In-hospital
ROOBY (Shroyer), 2009 NCT00032630	off-pump CABG versus on-pump CABG	patients scheduled for urgent or elective coronary bypass surgery	open Follow-up duration: 1 mo (1y) USA
Sahlman, 2003	versus		open
Selvanayagam, 2004	off-pump CABG versus on-pump CABG	patients undergoing multivessel CABG	open Follow-up duration: In-hospital
SMART (Staton), 2003	off-pump coronary artery bypass versus CABG with cardiopulmonary bypass	patients unselected for coronary anatomy, ventricular function, or comorbidities	open with blinded assessment Follow-up duration: 12 months US
Syed, 2004	versus		open
Tang, 2002	versus		open
Tatoulis, 2006	off-pump CABG versus on-pump CABG	candidates for elective CABG	open Follow-up duration: 30 days
Vedin, 2006	off-pump CABG versus on-pump CABG	patients between 50 and 80 years with stable angina pectoris, ejection fraction >30%, serum creatinine <150 micromol/l, and lack of tight main stem stenosis	open
Velisaris, 2003	versus		open
Vural, 1995	versus		open
Wan, 2004	versus		open
Wandschneider, 2000	versus		open
Zamvar, 2002	off-pump CABG versus on-pump CABG	patients undergoing coronary artery bypass graft surgery for triple vessel disease	open Follow-up duration: 10 weeks UK
preoperative atorvastatin versus placebo
Chello et al., 2006	preoperative atorvastatin 20 mg/d, started 3 wks before surgery versus placebo	elective CABG	double blind Follow-up duration: 7 days
Patti et al., 2006	preoperative atorvastatin 40 mg/d, starting 7 days before operation versus placebo	patients undergoing elective cardiac surgery with cardiopulmonary bypass, without previous statin treatment or history of AF	double blind Follow-up duration: 30 days
preoperative simvastatin versus no treatment
Christenson, 1999	preoperative simvastatin 20 mg/d, stated 4 weeks before surgery versus no statins	patients with hypercholesterolemia (total cholesterol > or =6.2 mmol/l) planned for CABG	Follow-up duration: 7 days
radial artery grafts versus saphenous vein grafts
RAPS (Desai), 2004 NCT00187356	group 1 versus group 2	patients undergoing bypass of the anterior circulation	open Follow-up duration: 12 months Canada, New Zealand
RSVP, 2008 NCT00139399	radial artery grafted to a stenosed branch of the native left circumflex coronary artery versus saphenous vein grafted to a stenosed branch of the native left circumflex coronary artery	patient undergoing CABG for a stenosed branch of the native left circumflex coronary artery	open Follow-up duration: 5 ans England
Gaudino (radial A), 2005	radial artery on the first obtuse marginal artery versus great saphenous vein graft on the first obtuse marginal artery	coronary artery bypass patients with previous in-stent restenosis (n=60) or not (n=60)	open Follow-up duration: 52 months Italy
VA CABG, 2010 NCT00054847	radial artery graft versus saphenous vein graft	patients with stable coronary artery disease	open Follow-up duration: 1 year (5y) USA
remote ischemic preconditioning versus control
Cheung, 2006	remote ischemic preconditioning versus control	children undergoing cardiac surgery for repair of congenital heart defects	open
Gunaydin, 2000	remote ischemic preconditioning versus control	patients undergoing coronary artery surgery	open
Hausenloy, 2007 NCT00397163	remote ischemic preconditioning versus	patients undergoing elective coronary artery bypass graft surgery	single blind
remote ischemic preconditioning versus no RIPC
Ali, 2007	remote ischemic preconditioningm versus without RIPC	patients undergoing elective open abdominal aortic aneurysm repair	open
right internal thoracic artery grafts versus saphenous vein grafts
Gaudino (RITA), 2005	right internal thoracic artery on the first obtuse marginal artery versus great saphenous vein graft on the first obtuse marginal artery	coronary artery bypass patients with previous in-stent restenosis (n=60) or not (n=60)	open Follow-up duration: 52 months Italy
sulfinpyrazone versus placebo
Baur, 1982	sulfinpyrazone 800 mg/day versus placebo	patients undergoing CABG	double blind Follow-up duration: 10d
sulotroban versus control
German sulotroban, 1989	ST versus		Follow-up duration: 21d
ticlopidine versus control
Zurich, 1982	ticlopidine 500 (NC) versus		Follow-up duration: 3m
Knudsen-B, 1983	ticlopidine 500 versus		Follow-up duration: 6m
Romeo, 1983	ticlopidine 500 versus		Follow-up duration: 3m (12m)
Kohn, 1990	ticlopidine 500 versus		Follow-up duration: 14d
ticlopidine versus placebo
Liège-I, 1984	ticlopidine 250 mg twice daily versus placebo	patients undergoing aortocoronary bypass graft procedures	double blind Follow-up duration: 3m
Liège-II, 1987	ticlopidine 250 mg twice daily versus placebo	patients undergoing venous coronary artery bypass grafting	double blind Follow-up duration: 12m
various versus placebo
Guiteras, 1989	aspirin 150 + dipiridamol 225, dipiridamol 225 + trifusal 900 versus placebo	patients undergoing coronary bypass grafting	double blind Follow-up duration: 7m
VA Co-op CABG, 1988	aspirin 325 daily, aspirin 325 three times daily, sulfinpyrazone, aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily) versus placebo	patients undergoing CABG	double blind Follow-up duration: 12m